Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.
Since Nov 17, 2025
Transactions
185
Purchases
0
Sales
185
Purchase value
$0.00
Sale value
$127.34M
Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.
Julie RubinsteinPresident and COO
4Rule 10b5-1 plan disclosed
Filed Nov 13, 2026Period of report Nov 11, 20260001780664-26-000055
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 13, 2026
Common StockF1F5
11,466
$28.93
$331.71K
377,802
Direct
SaleNov 12, 2026
Common StockF1F4
11,881
$29.40
$349.30K
377,802
Direct
SaleNov 11, 2026
Common StockF1F2
4,983
$30.29
$150.94K
384,700
Direct
SaleNov 11, 2026
Common StockF1F3
6,898
$31.22
$215.36K
377,802
Direct
Filing footnotes · 6
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.91 to $30.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.96 to $31.63, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.74 to $29.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.43 to $29.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Nov 10, 2026Period of report Nov 9, 20260001780664-26-000053
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 10, 2026
Common StockF1F5
9,981
$29.35
$292.94K
379,702
Direct
SaleNov 10, 2026
Common StockF1F6
1,900
$30.41
$57.78K
377,802
Direct
SaleNov 9, 2026
Common StockF1F2
1,100
$28.87
$31.76K
388,583
Direct
SaleNov 9, 2026
Common StockF1F3
8,381
$30.15
$252.69K
380,202
Direct
SaleNov 9, 2026
Common StockF1F4
2,400
$30.58
$73.39K
377,802
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.41 to $29.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.50 to $30.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.50 to $30.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.95, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.22 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Nov 6, 2026Period of report Nov 4, 20260001780664-26-000051
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 6, 2026
Common StockF1F7
8,400
$27.32
$229.49K
381,283
Direct
SaleNov 6, 2026
Common StockF1F8
3,481
$27.88
$97.05K
377,802
Direct
SaleNov 5, 2026
Common StockF1F4
5,926
$26.10
$154.67K
383,757
Direct
SaleNov 5, 2026
Common StockF1F5
5,455
$26.88
$146.63K
378,302
Direct
SaleNov 5, 2026
Common StockF1F6
500
$27.70
$13.85K
377,802
Direct
SaleNov 4, 2026
Common StockF1F2
4,000
$25.78
$103.12K
385,683
Direct
SaleNov 4, 2026
Common StockF1F3
7,881
$26.60
$209.63K
377,802
Direct
Filing footnotes · 9
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.26 to $26.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.26 to $26.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.55 to $26.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.56 to $27.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.59 to $27.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.65 to $27.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.65 to $28.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Nov 3, 2026Period of report Oct 30, 20260001780664-26-000049
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleNov 3, 2026
Common StockF1F6
11,881
$25.98
$308.67K
377,802
Direct
SaleNov 2, 2026
Common StockF1F4
9,296
$25.23
$234.54K
380,387
Direct
SaleNov 2, 2026
Common StockF1F5
2,585
$26.34
$68.09K
377,802
Direct
SaleOct 30, 2026
Common StockF1F2
9,486
$26.55
$251.85K
380,197
Direct
SaleOct 30, 2026
Common StockF1F3
2,395
$27.45
$65.74K
377,802
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $27.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.21 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.88 to $25.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.91 to $26.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.65 to $26.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 29, 2026Period of report Oct 27, 20260001780664-26-000047
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 29, 2026
Common StockF1F6
11,881
$28.27
$335.88K
377,802
Direct
SaleOct 28, 2026
Common StockF1F4
11,681
$28.44
$332.21K
378,002
Direct
SaleOct 28, 2026
Common StockF1F5
200
$28.90
$5.78K
377,802
Direct
SaleOct 27, 2026
Common StockF1F2
3,000
$26.58
$79.74K
386,683
Direct
SaleOct 27, 2026
Common StockF1F3
8,881
$27.53
$244.49K
377,802
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.04 to $27.02, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.07 to $27.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.85 to $28.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.88 to $28.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.92 to $28.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 26, 2026Period of report Oct 22, 20260001780664-26-000045
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 26, 2026
Common StockF1F6
8,503
$25.94
$220.57K
381,180
Direct
SaleOct 26, 2026
Common StockF1F7
3,378
$26.30
$88.84K
377,802
Direct
SaleOct 23, 2026
Common StockF1F4
4,500
$24.50
$110.25K
385,183
Direct
SaleOct 23, 2026
Common StockF1F5
7,381
$25.28
$186.59K
377,802
Direct
SaleOct 22, 2026
Common StockF1F2
10,181
$24.38
$248.21K
379,502
Direct
SaleOct 22, 2026
Common StockF1F3
1,700
$25.29
$42.99K
377,802
Direct
Filing footnotes · 8
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.96 to $24.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.96 to $25.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.82 to $24.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.85 to $25.60, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.25 to $26.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.25 to $26.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 21, 2026Period of report Oct 19, 20260001780664-26-000043
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 21, 2026
Common StockF1F4
5,999
$25.25
$151.47K
383,684
Direct
SaleOct 21, 2026
Common StockF1F5
5,882
$25.57
$150.40K
377,802
Direct
SaleOct 20, 2026
Common StockF1F3
11,781
$24.53
$288.99K
377,902
Direct
SaleOct 20, 2026
Common StockF1
100
$24.85
$2.49K
377,802
Direct
SaleOct 19, 2026
Common StockF1F2
11,881
$24.05
$285.74K
377,802
Direct
Filing footnotes · 6
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.88 to $24.85, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.84 to $24.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.44 to $25.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.44 to $25.73, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 16, 2026Period of report Oct 14, 20260001780664-26-000041
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 16, 2026
Common StockF1F5
11,581
$24.21
$280.38K
378,102
Direct
SaleOct 16, 2026
Common StockF1F6
300
$25.45
$7.64K
377,802
Direct
SaleOct 15, 2026
Common StockF1F4
11,881
$25.61
$304.27K
377,802
Direct
SaleOct 14, 2026
Common StockF1F2
6,781
$25.57
$173.39K
382,902
Direct
SaleOct 14, 2026
Common StockF1F3
5,100
$25.82
$131.68K
377,802
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.70 to $25.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.70 to $26.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.19 to $25.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.98 to $24.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.29 to $25.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 13, 2026Period of report Oct 9, 20260001780664-26-000039
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 13, 2026
Common StockF1F5
11,881
$25.50
$302.97K
377,802
Direct
SaleOct 12, 2026
Common StockF1F3
9,181
$25.35
$232.74K
380,502
Direct
SaleOct 12, 2026
Common StockF1F4
2,700
$26.07
$70.39K
377,802
Direct
SaleOct 9, 2026
Common StockF1F2
11,881
$26.41
$313.78K
377,802
Direct
Filing footnotes · 6
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 8, 2026Period of report Oct 6, 20260001780664-26-000037
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 8, 2026
Common StockF1F7
11,881
$25.66
$304.87K
377,802
Direct
SaleOct 7, 2026
Common StockF1F6
11,881
$26.40
$313.66K
377,802
Direct
SaleOct 6, 2026
Common StockF1F2
9,381
$27.36
$256.66K
380,302
Direct
SaleOct 6, 2026
Common StockF1F3
1,100
$28.21
$31.03K
379,202
Direct
SaleOct 6, 2026
Common StockF1F4
901
$29.71
$26.77K
378,301
Direct
SaleOct 6, 2026
Common StockF1F5
499
$30.53
$15.23K
377,802
Direct
Filing footnotes · 8
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.89 to $27.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.89 to $28.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $30.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.34 to $30.68, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.95 to $26.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.23 to $26.09, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 5, 2026Period of report Oct 1, 20260001780664-26-000035
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 5, 2026
Common StockF1F5
6,699
$28.82
$193.07K
382,984
Direct
SaleOct 5, 2026
Common StockF1F6
5,182
$29.67
$153.75K
377,802
Direct
SaleOct 2, 2026
Common StockF1F4
11,881
$28.13
$334.21K
377,802
Direct
SaleOct 1, 2026
Common StockF1F2
6,081
$27.57
$167.65K
383,602
Direct
SaleOct 1, 2026
Common StockF1F3
5,800
$28.56
$165.65K
377,802
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.11, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.22 to $28.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.62 to $28.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.30 to $29.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.32 to $29.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Oct 5, 2026Period of report Oct 1, 20260001780660-26-000024
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleOct 1, 2026
Common StockF1F2
8,094
$27.52
$222.75K
239,565
Direct
SaleOct 1, 2026
Common StockF1F3
18,698
$28.61
$534.95K
220,867
Direct
Filing footnotes · 6
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Sep 18, 2026Period of report Sep 16, 20260001780660-26-000022
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleSep 16, 2026
Common StockF1F2
107,537
$28.02
$3.01M
228,736
Direct
SaleSep 16, 2026
Common StockF1F3
7,869
$28.57
$224.82K
220,867
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.49 to $28.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.49 to $28.67, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The option is fully vested and exercisable.
F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F7The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Aug 20, 2026Period of report Aug 18, 20260001274139-26-000004
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 18, 2026
Common StockF1
15,000
$24.39
$365.85K
62,347
Direct
SaleAug 18, 2026
Common StockF2
15,664
$24.41
$382.36K
46,683
Direct
Filing footnotes · 3
F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.38 to $24.43, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.40 to $24.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The option was fully vested and exercisable and would have expired on October 18, 2026.
Filed Aug 19, 2026Period of report Aug 17, 20260001780649-26-000014
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 18, 2026
Common StockF3
278,472
$24.48
$6.82M
2,180,722
Direct
SaleAug 18, 2026
Common StockF4
204
$25.14
$5.13K
2,180,518
Direct
SaleAug 17, 2026
Common StockF1
318,799
$25.08
$8.00M
2,183,043
Direct
SaleAug 17, 2026
Common StockF2
2,525
$25.57
$64.56K
2,180,518
Direct
Filing footnotes · 5
F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The option was fully vested and exercisable and would have expired on February 7, 2028.
Filed Aug 19, 2026Period of report Aug 17, 20260001237566-26-000003
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleAug 17, 2026
Common StockF1
15,000
$25.23
$378.45K
240,315
Direct
SaleAug 17, 2026
Common StockF2
40,000
$25.10
$1.00M
200,315
Direct
SaleAug 17, 2026
Common StockF3
69,690
$25.16
$1.75M
130,625
Direct
Filing footnotes · 4
F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.21 to $25.27, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.17, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.14 to $25.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The option was fully vested and exercisable and would have expired on October 18, 2026.
Filed Jul 23, 2026Period of report Jul 21, 20260001780851-26-000017
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 21, 2026
Common StockF1F2
278,698
$21.72
$6.05M
1,025,760
Direct
SaleJul 21, 2026
Common StockF1F3
213,702
$22.12
$4.73M
812,058
Direct
Filing footnotes · 4
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Jul 17, 2026Period of report Jul 15, 20260001780660-26-000019
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 15, 2026
Common StockF1F2
105,762
$22.59
$2.39M
230,713
Direct
Filing footnotes · 4
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.78, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The option is fully vested and exercisable.
F4The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Jul 7, 2026Period of report Jul 2, 20260001780851-26-000015
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 2, 2026
Common StockF1F2
239,351
$21.74
$5.20M
1,166,547
Direct
SaleJul 2, 2026
Common StockF1F3
146,889
$22.45
$3.30M
1,019,658
Direct
Filing footnotes · 3
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.15 to $22.145, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $22.15 to $22.75, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Jul 6, 2026Period of report Jul 1, 20260001780660-26-000017
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJul 2, 2026
Common StockF1F4
44,838
$22.59
$1.01M
230,713
Direct
SaleJul 1, 2026
Common StockF1F2
8,743
$22.18
$193.92K
279,949
Direct
SaleJul 1, 2026
Common StockF1F3
42,261
$22.50
$950.87K
237,688
Direct
Filing footnotes · 8
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The option is fully vested and exercisable.
F6The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F7The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F8The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Jun 30, 2026Period of report Jun 26, 20260001780854-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 29, 2026
Common StockF1F3
154,768
$21.14
$3.27M
221,278
Direct
SaleJun 26, 2026
Common StockF1F2
11,034
$21.00
$231.71K
272,751
Direct
Filing footnotes · 7
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The option was fully vested and exercisable.
F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F7The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Jun 29, 2026Period of report Jun 25, 20260001229765-26-000008
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 25, 2026
Common StockF1F2
52,084
$20.18
$1.05M
15,625
Direct
Filing footnotes · 3
F1The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Jun 17, 2026Period of report Jun 15, 20260001780851-26-000013
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 16, 2026
Common StockF1F3
6,160
$18.01
$110.94K
1,405,898
Direct
SaleJun 15, 2026
Common StockF1F2
100,000
$17.37
$1.74M
1,412,058
Direct
Filing footnotes · 3
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.14 to $17.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $18.00 to $18.04, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Jun 8, 2026Period of report Jun 4, 20260001780660-26-000015
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleJun 4, 2026
Common StockF1
39,741
$17.49
$695.07K
250,934
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The option is fully vested and exercisable.
F3The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F4The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed May 20, 2026Period of report May 18, 20260001780662-26-000013
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMay 18, 2026
Common StockF1
3,115
$13.04
$40.62K
256,725
Direct
Filing footnotes · 1
F1This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Filed Apr 29, 2026Period of report Apr 27, 20260001780664-26-000032
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 27, 2026
Common StockF1F2
19,037
$14.23
$270.90K
377,802
Direct
Filing footnotes · 3
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.08 to $14.34, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Apr 24, 2026Period of report Apr 22, 20260001780664-26-000030
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 24, 2026
Common StockF1F4
19,060
$14.02
$267.22K
382,132
Direct
SaleApr 23, 2026
Common StockF1F3
19,060
$13.74
$261.88K
386,470
Direct
SaleApr 22, 2026
Common StockF1F2
19,060
$14.13
$269.32K
390,808
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.97 to $14.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.52 to $14.14, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $14.16, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Apr 21, 2026Period of report Apr 17, 20260001780664-26-000028
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 21, 2026
Common StockF1F4
30,941
$14.66
$453.60K
395,146
Direct
SaleApr 20, 2026
Common StockF1F3
19,060
$14.55
$277.32K
399,484
Direct
SaleApr 17, 2026
Common StockF1F2
19,060
$14.57
$277.70K
403,822
Direct
Filing footnotes · 6
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.38 to $14.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.14 to $14.82, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.18 to $15.13, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Apr 16, 2026Period of report Apr 14, 20260001780664-26-000026
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 16, 2026
Common StockF1F4
19,060
$14.18
$270.27K
408,160
Direct
SaleApr 15, 2026
Common StockF1F3
19,060
$14.61
$278.47K
412,498
Direct
SaleApr 14, 2026
Common StockF1F2
19,060
$14.56
$277.51K
416,836
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.17 to $14.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.49 to $14.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Apr 13, 2026Period of report Apr 9, 20260001780664-26-000024
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 13, 2026
Common StockF1F6
15,722
$12.95
$203.60K
424,512
Direct
SaleApr 13, 2026
Common StockF1F7
3,338
$14.08
$47.00K
421,174
Direct
SaleApr 10, 2026
Common StockF1F4
18,660
$12.75
$237.92K
425,912
Direct
SaleApr 10, 2026
Common StockF1F5
400
$13.48
$5.39K
425,512
Direct
SaleApr 9, 2026
Common StockF1F2
16,960
$13.79
$233.88K
431,950
Direct
SaleApr 9, 2026
Common StockF1F3
2,100
$14.44
$30.32K
429,850
Direct
Filing footnotes · 9
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.40 to $14.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.62, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.43 to $13.42, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F7The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.87 to $14.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F8The option is fully vested and exercisable.
F9The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Apr 10, 2026Period of report Apr 8, 20260001780851-26-000011
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 8, 2026
Common StockF1F2
10,000
$14.85
$148.50K
1,512,058
Direct
Filing footnotes · 2
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $14.65 to $15.06, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Apr 10, 2026Period of report Apr 8, 20260001780660-26-000013
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 8, 2026
Common StockF1F2
22,564
$15.07
$340.04K
271,154
Direct
Filing footnotes · 3
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Filed Apr 8, 2026Period of report Apr 6, 20260001780664-26-000022
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 8, 2026
Common StockF1F4
30,841
$14.83
$457.37K
434,288
Direct
SaleApr 8, 2026
Common StockF1
100
$15.48
$1.55K
434,188
Direct
SaleApr 7, 2026
Common StockF1F3
19,060
$13.56
$258.45K
438,526
Direct
SaleApr 6, 2026
Common StockF1F2
19,060
$14.33
$273.13K
442,864
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.86, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.39 to $13.83, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $15.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Apr 8, 2026Period of report Apr 6, 20260001780649-26-000011
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 8, 2026
Common StockF1F3
37,263
$15.19
$566.02K
2,180,518
Direct
SaleApr 6, 2026
Common StockF1F2
83,332
$14.41
$1.20M
2,217,781
Direct
Filing footnotes · 3
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.19 to $14.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Apr 2, 2026Period of report Apr 1, 20260001780664-26-000020
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleApr 2, 2026
Common StockF1F3
19,060
$14.60
$278.28K
447,202
Direct
SaleApr 1, 2026
Common StockF1F2
19,060
$14.45
$275.42K
451,540
Direct
Filing footnotes · 4
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.89 to $14.88, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Mar 31, 2026Period of report Mar 27, 20260001780664-26-000018
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 31, 2026
Common StockF1F5
19,060
$13.45
$256.36K
455,878
Direct
SaleMar 30, 2026
Common StockF1F4
19,060
$12.63
$240.73K
460,216
Direct
SaleMar 27, 2026
Common StockF1F2
2,738
$12.49
$34.20K
480,876
Direct
SaleMar 27, 2026
Common StockF1F3
16,322
$13.48
$220.02K
464,554
Direct
Filing footnotes · 6
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.07 to $12.98, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.14 to $13.84, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.10 to $13.87, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Mar 26, 2026Period of report Mar 24, 20260001780664-26-000016
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 26, 2026
Common StockF1F4
19,060
$14.12
$269.13K
468,892
Direct
SaleMar 25, 2026
Common StockF1F3
19,060
$14.27
$271.99K
473,230
Direct
SaleMar 24, 2026
Common StockF1F2
19,060
$13.70
$261.12K
477,568
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.45 to $13.92, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.98 to $14.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.82 to $14.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Mar 23, 2026Period of report Mar 19, 20260001780664-26-000014
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 23, 2026
Common StockF1F4
19,060
$13.83
$263.60K
481,906
Direct
SaleMar 20, 2026
Common StockF1F3
19,060
$13.37
$254.83K
486,244
Direct
SaleMar 19, 2026
Common StockF1F2
19,060
$13.18
$251.21K
490,582
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.53, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.59, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.51 to $14.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Filed Mar 18, 2026Period of report Mar 16, 20260001780664-26-000012
Transaction
Security
Shares
Price
ValueValue (shares × price)
Held after
Ownership
SaleMar 18, 2026
Common StockF1F4
19,060
$13.18
$251.21K
494,920
Direct
SaleMar 17, 2026
Common StockF1F3
19,060
$13.40
$255.40K
499,258
Direct
SaleMar 16, 2026
Common StockF1F2
19,060
$13.41
$255.59K
503,596
Direct
Filing footnotes · 5
F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.26 to $13.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.23 to $13.61, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.37, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.